A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer

HFCAS OpenIR

	A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer
其他题名	A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer
	2016
发表期刊	CHINESE JOURNAL OF CANCER RESEARCH
ISSN	1000-9604
摘要	Objective: This study aims to investigate the feasibility, safety and efficacy of triplet regimen of neoadjuvant chemotherapy in patients with locally advanced resectable colon cancer.
其他摘要	Objective This study aims to investigate the feasibility, safety and efficacy of triplet regimen of neoadjuvant chemotherapy in patients with locally advanced resectable colon cancer. Methods Patients with clinical stage IIIb colon cancer received a perioperative triple chemotherapy regimen (oxaliplatin 85 mg 2 and irinotecan 150 mg 2 , combined with folinic acid 200 mg, 5-fluorouracil 500 mg bolus and then 2,400 mg 2 by 44 h infusion or capecitabine 1 g 2 or S-1 40–60 mg b.i.d orally d 1–10, repeated at 2-week intervals) for 4 cycles. Complete mesocolic excision was scheduled 2–6 weeks after completion of neoadjuvant treatment and followed by a further 6 cycles of FOLFOXIRI or XELOX. Primary outcome measures of this stage II trial were feasibility, safety, tolerance and efficacy of neoadjuvant treatment. Results All 23 patients received neoadjuvant chemotherapy and underwent surgery. Twenty-one patients (91.3%) had reductions in tumor volume after neoadjuvant treatment, and 13 patients (56.5%) had grade 3–4 toxicity. No patients had severe complications from surgery. Preoperative therapy resulted in significant down-staging of T-stage and N-stage compared with the baseline clinical stage including one pathological complete response. Conclusions Neoadjuvant triple chemotherapy has high activity and acceptable toxicity and perioperative morbidity, and is feasible, tolerable and effective for locally advanced resectable colon cancer.
关键词	METASTATIC COLORECTAL-CANCER 1ST-LINE TREATMENT ADJUVANT CHEMOTHERAPY PATHOLOGICAL RESPONSE LIVER METASTASES STAGE-II OXALIPLATIN FLUOROURACIL LEUCOVORIN IRINOTECAN 5-Fluorouracil colon cancer irinotecan oxaliplatin neoadjuvant chemotherapy
收录类别	CSCD
语种	英语
CSCD记录号	CSCD:5880712
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/56973
专题	中国科学院合肥物质科学研究院
推荐引用方式 GB/T 7714	. A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer[J]. CHINESE JOURNAL OF CANCER RESEARCH,2016,28.
APA	(2016).A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer.CHINESE JOURNAL OF CANCER RESEARCH,28.
MLA	"A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer".CHINESE JOURNAL OF CANCER RESEARCH 28(2016).